Leptin increases osteoblast-specific osteocalcin release through a hypothalamic relay

Peptides

Volumn 30, Issue 5, 2009, Pages 967-973

  Kalra, Satya P ^a   Dube, Michael G ^a   Iwaniec, Urszula T ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

Bone remodeling; Glucose insulin homeostasis; Hypothalamus; Leptin; Osteoblast; Osteocalcin

Indexed keywords

GREEN FLUORESCENT PROTEIN; HYPOTHALAMUS HORMONE; INSULIN; LEPTIN; OSTEOCALCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE GROWTH; CONTROL GROUP; CONTROLLED STUDY; DIABETES MELLITUS; GENE THERAPY; GENOTYPE; HYPOTHALAMUS FUNCTION; INSULIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

ANIMALS; BLOOD GLUCOSE; DEPENDOVIRUS; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HYPOTHALAMUS; INSULIN; LEPTIN; MALE; MICE; OSTEOBLASTS; OSTEOCALCIN;

ADENO-ASSOCIATED VIRUS; MUS;

EID: 67349253844     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2009.01.020     Document Type: Article

References (66)

1. Bagnasco M., Dube M.G., Kalra P.S., and Kalra S.P. Evidence for the existence of distinct central appetite and energy expenditure pathways and stimulation of ghrelin as revealed by hypothalamic site-specific leptin gene therapy. Endocrinology 143 (2002) 4409-4421
2. Bagnasco M., Dube M.G., Katz A., Kalra P.S., and Kalra S.P. Leptin expression in hypothalamic PVN reverses dietary obesity and hyperinsulinemia but stimulates ghrelin. Obes Res 11 (2003) 1463-1470
3. Baldock P.A., Allison S.J., Lundberg P., Lee N.J., Slack K., Lin E.J., et al. Novel role of Y1 receptors in the coordinated regulation of bone and energy homeostasis. J Biol Chem 282 (2007) 19092-19102
4. Baldock P.A., Sainsbury A., Allison S., Lin E.J.D., Couzens M.D.B., Enriquez R., et al. Hypothalamic control of bone formation: distinct actions of leptin and Y2 receptor pathways. J Bone Miner Res 20 (2005) 1851-1857
5. Baldock P.A., Sainsbury A., Couzens M., Enriquez R., Thomas G.P., Gardiner E.M., et al. Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 109 (2002) 915-921
6. Bamshad M., Song C.K., and Bartness T.J. CNS origins of the sympathetic nervous system outflow to brown adipose tissue. Am J Physiol 276 (1999) R1569-R1578
7. Banks W.A., Kastin A.J., Huang W., Jaspan J.B., and Maness L.M. Leptin enters the brain by a saturable system independent of insulin. Peptides 17 (1996) 305-311
8. Baratta M. Leptin-from a signal of adiposity to a hormonal mediator in peripheral tissues. Med Sci Monit 8 (2002) RA282-RA292
9. Bartness T.J., Kay Song C., Shi H., Bowers R.R., and Foster M.T. Brain-adipose tissue cross talk. Proc Nutr Soc 64 (2005) 53-64
10. Boghossian S., Dube M.G., Torto R., Kalra P.S., and Kalra S.P. Hypothalamic clamp on insulin release by leptin-transgene expression. Peptides 27 (2006) 3245-3254
11. Boghossian S., Lecklin A.H., Torto R., Kalra P.S., and Kalra S.P. Suppression of fat deposition for the life time of rodents with gene therapy. Peptides 26 (2005) 1512-1519
12. Boghossian S., Ueno N., Dube M.G., Kalra P.S., and Kalra S.P. Leptin gene transfer in the hypothalamus enhances longevity in adult monogenic mutant mice in the absence of circulating leptin. Neurobiol Aging 28 (2007) 1594-1604
13. Buijs R.M., Chun S.J., Niijima A., Romijn H.J., and Nagai K. Parasympathetic and sympathetic control of the pancreas: a role for the suprachiasmatic nucleus and other hypothalamic centers that are involved in the regulation of food intake. J Comp Neurol 431 (2001) 405-423
14. Campfield L.A., Smith F.J., Guisez Y., Devos R., and Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks [see comments]. Science 269 (1995) 546-549
15. Chan M.H., Mak T.W., Chiu R.W., Chow C.C., Chan I.H., and Lam C.W. Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia. J Clin Endocrinol Metab 86 (2001) 4556-4559
16. Chen Y., and Heiman M.L. Chronic leptin administration promotes lipid utilization until fat mass is greatly reduced and preserves lean mass of normal female rats. Regul Pept 92 (2000) 113-119
17. Chinookoswong N., Wang J.L., and Shi Z.Q. Leptin restores euglycemia and normalizes glucose turnover in insulin-deficient diabetes in the rat. Diabetes 48 (1999) 1487-1492
18. Cirmanova V., Bayer M., Starka L., and Zajickova K. The effect of leptin on bone-an evolving concept of action. Physiol Res 57 (2008) S143-S151
19. Della-Fera M.A., Choi Y.H., Hartzell D.L., Duan J., Hamrick M., and Baile C.A. Sensitivity of ob/ob mice to leptin-induced adipose tissue apoptosis. Obes Res 13 (2005) 1540-1547
20. Dhillon H., Ge Y., Minter R.M., Prima V., Moldawer L.L., Muzyczka N., et al. Long-term differential modulation of genes encoding orexigenic and anorexigenic peptides by leptin delivered by rAAV vector in ob/ob mice. Relationship with body weight change. Regul Pept 92 (2000) 97-105
21. Dhillon H., Kalra S.P., Prima V., Zolotukhin S., Scarpace P.J., Moldawer L.L., et al. Central leptin gene therapy suppresses body weight gain, adiposity and serum insulin without affecting food consumption in normal rats: a long-term study. Regul Pept 99 (2001) 69-77
22. Dube M.G., Torto R., and Kalra S.P. Increased leptin expression selectively in the hypothalamus suppresses inflammatory markers CRP and IL-6 in leptin-deficient diabetic obese mice. Peptides 29 (2008) 593-598
23. Ducy P., Amling M., Takeda S., Priemel M., Schilling A.F., Beil F.T., et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100 (2000) 197-207
24. Ducy P., Desbois C., Boyce B., Pinero G., Story B., Dunstan C., et al. Increased bone formation in osteocalcin-deficient mice. Nature 382 (1996) 448-452
25. Ealey K.N., Fonseca D., Archer M.C., and Ward W.E. Bone abnormalities in adolescent leptin-deficient mice. Regul Pept 136 (2006) 9-13
26. Elefteriou F., Takeda S., Ebihara K., Magre J., Patano N., Ae Kim C., et al. Serum leptin level is a regulator of bone mass. PNAS 101 (2004) 3258-3263
27. Evans R.M., Grey A., and Clarke B.L. Three perspectives on thiazolidine and bone health. Endocrine News (2008) 14-21
28. Ferron M., Hinoi E., Karsenty G., and Ducy P. Osteocalcin differentially regulates β cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. PNAS 105 (2008) 5266-5270
29. Friedman J.M., and Halaas J.L. Leptin and the regulation of body weight in mammals. Nature 395 (1998) 763-770
30. Guidobono F., Pagani F., Sibilia V., Netti C., Lattuada N., Rapetti D., et al. Different skeletal regional response to continuous brain infusion of leptin in the rat. Peptides 27 (2006) 1426-1433
31. Hamrick M.W., Della-Fera M.A., Choi Y.H., Pennington C., Hartzell D., and Baile C.A. Leptin treatment induces loss of bone marrow adipocytes and increases bone formation in leptin-deficient ob/ob mice. J Bone Miner Res 20 (2005) 994-1001
32. Harada S.-i., and Rodan G.A. Control of osteoblast function and regulation of bone mass. Nature 423 (2003) 349-355
33. Hidaka S., Yoshimatsu H., Kondou S., Tsuruta Y., Oka K., Noguchi H., et al. Chronic central leptin infusion restores hyperglycemia independent of food intake and insulin level in streptozotocin-induced diabetic rats. FASEB J 16 (2002) 509-518
34. Hinoi E., Gao N., Jung D.Y., Yadav V., Yoshizawa T., Myers Jr. M.G., et al. The sympathetic tone mediates leptin's inhibition of insulin secretion by modulating osteocalcin bioactivity. J Cell Biol 183 (2008) 1235-1242
35. Iwaniec U.T., Boghossian S., Lapke P.D., Turner R.T., and Kalra S.P. Central leptin gene therapy corrects skeletal abnormalities in leptin-deficient ob/ob mice. Peptides 28 (2007) 1012-1019
36. Iwaniec U.T., Dube M.G., Boghossian S., Song H., Helferich W.G., Turner R.T., et al. Body mass influences cortical bone mass independent of leptin signaling. Bone 44 (2009) 404-412
37. Kalra S.P. Central leptin insufficiency syndrome: an interactive etiology for obesity, metabolic and neural diseases and for designing new therapeutic interventions. Peptides 29 (2008) 127-138
38. Kalra S.P. Disruption in the leptin-NPY link underlies the pandemic of diabetes and metabolic syndrome: new therapeutic approaches. Nutrition 24 (2008) 820-826
39. Kalra S.P., Dube M.G., Pu S., Xu B., Horvath T.L., and Kalra P.S. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 20 (1999) 68-100
40. Kalra S.P., and Kalra P.S. Gene transfer technology: a preventive neurotherapy to curb obesity, ameliorate metabolic syndrome and extend life-expectancy. Trends Pharmacol Sci 26 (2005) 488-495
41. Kalra S.P., and Kalra P.S. NPY and cohorts in regulating appetite, obesity and metabolic syndrome: beneficial effects of gene therapy. Neuropeptides 38 (2004) 201-211
42. Kastin A.J., and Pan W. Dynamic regulation of leptin entry into brain by the blood-brain barrier. Regul Pept 92 (2000) 37-43
43. Kastin A.J., and Pan W. Intranasal leptin: blood-brain barrier bypass (BBBB) for obesity?. Endocrinology 147 (2006) 2086-2087
44. Kreier F., Kap Y.S., Mettenleiter T.C., van Heijningen C., van der Vliet J., Kalsbeek A., et al. Tracing from fat tissue, liver, and pancreas: a neuroanatomical framework for the role of the brain in type 2 diabetes. Endocrinology 147 (2006) 1140-1147
45. Lecklin A.H., Dube M.G., Torto R., Kalra P.S., and Kalra S.P. Perigestational suppression of weight gain with central leptin gene therapy results in lower weight F1 generation. Peptides 26 (2005) 1176-1187
46. Lee N.K., and Karsenty G. Reciprocal regulation of bone and energy metabolism. Trends Endocrinol Metab 19 (2008) 161-166
47. Lord G. Role of leptin in immunology. Nutr Rev 60 (2002) S35-38, S68-87
48. Lundberg P., Allison S.J., Lee N.J., Baldock P.A., Brouard N., Rost S., et al. Greater bone formation of Y2 knockout mice is associated with increased osteoprogenitor numbers and altered Y1 receptor expression. J Biol Chem 282 (2007) 19082-19091
49. Maness L.M., Kastin A.J., Farrell C.L., and Banks W.A. Fate of leptin after intracerebroventricular injection into the mouse brain. Endocrinology 139 (1998) 4556-4562
50. Otukonyong E.E., Dube M.G., Torto R., Kalra P.S., and Kalra S.P. Central leptin differentially modulates ultradian secretory patterns of insulin, leptin and ghrelin independent of effects on food intake and body weight. Peptides 26 (2005) 2559-2566
51. Patel M.S., and Elefteriou F. The new field of neuroskeletal biology. Calc Tissue Int 80 (2007) 337-347
52. Ruiz-Gaspa S., Nogues X., Enjuanes A., Monllau J.C., Blanch J., Carreras R., et al. Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG-63 cultures. J Cell Biochem 101 (2007) 1430-1438
53. Sahu A. Resistance to the satiety action of leptin following chronic central leptin infusion is associated with the development of leptin resistance in neuropeptide Y neurones. J Neuroendocrinol 14 (2002) 796-804
54. Seeman E. Structural basis of growth-related gain and age-related loss of bone strength. Rheumatology 47 (2008) iv2-iv8
55. Shi Z.Q., Nelson A., Whitcomb L., Wang J., and Cohen A.M. Intracerebroventricular administration of leptin markedly enhances insulin sensitivity and systemic glucose utilization in conscious rats. Metabolism 47 (1998) 1274-1280
56. Sierra-Honigmann M.R., Nath A.K., Murakami C., Garcia-Cardena G., Papapetropoulos A., Sessa W.C., et al. Biological action of leptin as an angiogenic factor. Science 281 (1998) 1683-1686
57. Takeda S., Elefteriou F., Levasseur R., Liu X., Zhao L., Parker K.L., et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 111 (2002) 305-317
58. Thomas T. The complex effects of leptin on bone metabolism through multiple pathways. Curr Opin Pharmacol 4 (2004) 295-300
59. Ueno N., Dube M.G., Inui A., Kalra P.S., and Kalra S.P. Leptin modulates orexigenic effects of ghrelin and attenuates adiponectin and insulin levels and selectively the dark-phase feeding as revealed by central leptin gene therapy. Endocrinology 145 (2004) 4176-4184
60. Ueno N., Inui A., Kalra S.P., and Kalra P.S. Leptin transgene expression in the hypothalamus enforces euglycemia in diabetic, insulin-deficient nonobese Akita mice and leptin-deficient obese ob/ob mice. Peptides 27 (2006) 2332-2342
61. Uyama N., Geerts A., and Reynaert H. Neural connections between the hypothalamus and the liver. Anat Rec A Discov Mol Cell Evol Biol 280 (2004) 808-820
62. Wang J., Takeuchi T., Tanaka S., Kubo S.K., Kayo T., Lu D., et al. A mutation in the insulin 2 gene induces diabetes with severe pancreatic beta-cell dysfunction in the Mody mouse. J Clin Invest 103 (1999) 27-37
63. Whitfield JF. PTH and leptin: two bone builders at the Alamo. Part 2: leptin; 2002. medscape.com.
64. Wolf G. Energy regulation by the skeleton. Nutr Rev 66 (2008) 229-233
65. Wynne K., Stanley S., McGowan B., and Bloom S. Appetite control. J Endocrinol 184 (2005) 291-318
66. Yoshioka M., Kayo T., Ikeda T., and Koizumi A. A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice. Diabetes 46 (1997) 887-894